相关临床试验
63
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2014
进行中（未招募）
2
3.2%
已完成
37
58.7%
尚未招募
1
1.6%
招募中
10
15.9%
暂停
1
1.6%
终止
2
3.2%
Unknown
8
12.7%
撤回
2
3.2%
暂无批准数据
- An international research team identified the EFEMP1 p.Arg140Trp variant as the cause of a previously unrecognized inherited retinal degeneration affecting peripheral and night vision. - The newly described condition, provisionally termed EFEMP1-associated late-onset retinal degeneration (L-ORD), was found in three unrelated families across multiple countries. - Rod photoreceptor dysfunction can be detected before visible structural retinal damage, providing a functional marker at a stage when photoreceptor cells remain intact. - Researchers do not yet know how widespread the variant is and say larger studies are needed to determine its prevalence and patient population size.
- Researchers at the University of Basel screened 1,642 compounds across patient-derived hepatocellular carcinoma organoids to identify effective drug combinations. - A triple combination of regorafenib, selinexor, and ixazomib slowed tumor growth more effectively than regorafenib alone in mouse models without significant additional toxicity. - The 35-organoid collection, built partly from diagnostic needle biopsies, captures advanced tumors and diverse disease stages previously underrepresented in existing models. - Findings remain preclinical, as organoids do not fully reproduce the tumor microenvironment, including blood vessels and immune cells.
- A UC Irvine-led study published in Nature Communications found that Greenland sharks, the longest-living vertebrates, show no signs of retinal degeneration despite living up to 400 years. - Researchers identified a DNA repair mechanism that may protect the shark retina from age-related decline, with rhodopsin remaining active and tuned to blue light for low-light vision. - The findings challenge the long-held assumption that Greenland sharks are functionally blind due to eye parasites and their dark Arctic habitat. - The work may eventually inform research on age-related human eye diseases such as macular degeneration and glaucoma.
- The ComBaScale project, funded by Horizon Europe, will train community health workers in Lesotho to deliver integrated care for hypertension, diabetes, HIV, and tuberculosis. - A dedicated mobile app will guide community health workers through safe, up-to-date treatment decisions for cardiovascular risk factor management. - The stepped-wedge trial will evaluate cost-effectiveness and explore barriers such as stigma and gender dynamics, with community members actively shaping the programme. - Nine partners across Lesotho, Switzerland, Belgium, South Africa, Germany, and the UK will collaborate, coordinated by ITM's Unit of HIV and TB.
- A landmark study published in Brain journal validates that combined GFAP and NfL blood biomarkers provide comprehensive monitoring of multiple sclerosis disease activity and progression. - Elevated serum GFAP levels were significantly associated with increased risk of Progression Independent of Relapse Activity (PIRA), addressing the "biggest unmet therapeutic need in MS." - Quanterix's Simoa technology enables simultaneous measurement of both biomarkers with extensive normative databases for individual patient interpretation. - The dual biomarker approach offers clinicians a complete picture by monitoring both acute inflammatory activity and insidious disease progression in MS patients.
- Researchers at the University of Basel have developed a novel fusion protein that combines an improved interleukin-2 signaling molecule with an antibody to simultaneously block cancer cells' "do not attack" signals and activate tumor-targeting immune cells. - The molecule addresses key limitations of traditional IL-2 therapy by avoiding activation of immune-suppressing cells while specifically targeting tumor-fighting immune cells in laboratory experiments with lung cancer patient samples. - Roche has initiated a Phase I clinical trial to test the fusion protein, marking a significant advancement in precision cancer immunotherapy after 40 years of IL-2-based treatments. - Laboratory studies published in Science Translational Medicine demonstrate the molecule's ability to selectively activate immune cells that eliminate abnormal cells without strengthening tumor-protective mechanisms.
- The SECA randomized clinical trial found no significant difference in recurrence rates between patients who continued low-dose aspirin versus placebo after chronic subdural hematoma surgery, with reoperation rates of 13.9% and 9.5% respectively. - Cardiovascular and thromboembolic event rates were similar between groups, but patients continuing aspirin experienced fewer cardiovascular events (0.02 vs 0.06 per person) over six months. - The findings challenge current practice patterns of routine aspirin discontinuation and suggest recurrence risks under continued aspirin therapy are lower than previously estimated from observational studies. - Results support individualized risk assessment rather than blanket aspirin cessation, potentially reducing unwarranted treatment interruptions in this vulnerable elderly population.
- Researchers at University of Basel and Roche used CRISPR/Cas9 screening to identify genes that significantly influence antisense oligonucleotide (ASO) activity, revealing that intracellular transport speed is a critical determinant of therapeutic efficacy. - The study found that prolonging ASO residence time in endosomes by targeting the AP1M1 gene dramatically improves drug effectiveness without requiring higher doses, offering a new strategy for treating genetic diseases like ALS and Duchenne muscular dystrophy. - This breakthrough demonstrates that optimizing intracellular trafficking pathways, rather than just drug design, could enhance RNA-based therapies and potentially provide novel antimicrobial strategies against bacterial and viral pathogens.
- Swiss regulatory authorities Swissmedic and Swissethics have jointly issued updated position paper on decentralized clinical trials, marking a significant step in modernizing clinical research frameworks. - The new guidelines aim to streamline the implementation of decentralized clinical trials while maintaining rigorous safety and quality standards in pharmaceutical research. - This regulatory update positions Switzerland at the forefront of adapting clinical trial methodologies to embrace digital health technologies and remote patient monitoring.
- University of Basel researchers demonstrate Angle's Parsortix system can capture over 99% of circulating tumor cell clusters from blood samples, enabling breakthrough metastasis prevention research. - FDA-approved drugs identified through the system successfully disrupted cancer cell clusters in mouse models, reducing metastasis by 80-fold without typical chemotherapy side effects. - Clinical trials planned for 2019 will use Parsortix as a companion diagnostic in breast cancer patients to identify those who may benefit from cluster-disrupting therapy.
